Amgen in new talks over ESA safety

Amgen is sitting down with regulators for a little frank talk about the safety warnings on Aranesp and Epogen, its two cash cows in the anemia market that were worth $6.6 billion in revenue last year. The biotech giant also says that the Oncologic Drugs Advisory Committee plans to meet and review the ESA drugs in the first quarter of next year. Revenue from the ESA category has been falling steadily as federal and private payers enforce limits on their use. That trend has forced Amgen to restructure and pay more attention to pipeline development projects.

- here's the AFX report on Amgen

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.